We are live on
!
Find out more
SM
SG3 Management Portfolio holdings
AUM
$6.45K
1-Year Est. Return
61.81%
This Fund
S&P 500
This Quarter
Est. Return
+2.7%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
–
AUM
$746M
AUM Growth
-$106M
(-12%)
Cap. Flow
-$67.1M
Cap. Flow
% of AUM
-9%
Top 10 Holdings %
Top 10 Hldgs %
44.28%
Holding
510
New
122
Increased
34
Reduced
59
Closed
238
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$49.5M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$21.8M |
| 3 |
Walt Disney
DIS
|
+$16.1M |
| 4 |
Microsoft
MSFT
|
+$11M |
| 5 |
TSMC
TSM
|
+$8.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KraneShares CSI China Internet ETF
KWEB
|
+$6.55M |
| 2 |
Bausch Health
BHC
|
+$5.35M |
| 3 |
Digital Realty Trust
DLR
|
+$1.95M |
| 4 |
PennyMac Financial
PFSI
|
+$1.67M |
| 5 |
ConocoPhillips
COP
|
+$1.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 7.31% |
| 2 | Communication Services | 4.95% |
| 3 | Technology | 3.75% |
| 4 | Energy | 1.57% |
| 5 | Healthcare | 1.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
CALL
Altimmune
ALT
$568M
| $298K | 0.04% |
+23,300
| New | +$344K |
|
177
CALL
Intellia Therapeutics
NTLA
$1.51B
| $280K | 0.04% |
5,000
-15,700
| -76% | -$974K |
|
178
Universal Insurance Holdings
UVE
$1.26B
| $274K | 0.04% |
+27,804
| New | +$333K |
|
|
179
CALL
Bausch Health
BHC
$1.75B
| $270K | 0.04% |
39,200
-196,000
| -83% | -$1.36M |
|
180
CALL
Enovix
ENVX
$803M
| $268K | 0.04% |
+16,686
| New | +$246K |
|
|
AKRO
181
CALL
DELISTED
Akero Therapeutics
AKRO
| $262K | 0.04% |
+7,700
| New | +$118K |
|
|
AKRO
182
PUT
DELISTED
Akero Therapeutics
AKRO
| $262K | 0.04% |
+7,700
| New | +$118K |
|
183
ADT
ADT
$5.43B
| $262K | 0.04% |
35,000
+10,000
| +40% | +$75.4K |
|
184
CALL
Ultragenyx Pharmaceutical
RARE
$2.46B
| $261K | 0.04% |
+6,300
| New | +$324K |
|
185
CALL
Barclays
BCS
$87.8B
| $256K | 0.03% |
40,000
-1,300
| -3% | -$10K |
|
186
CALL
Dave & Buster's
PLAY
$357M
| $254K | 0.03% |
8,200
-50,000
| -86% | -$1.87M |
|
187
Amphastar Pharmaceuticals
AMPH
$907M
| $249K | 0.03% |
+8,878
| New | +$290K |
|
188
Cheniere Energy
LNG
$54.2B
| $249K | 0.03% |
+1,500
| New | +$228K |
|
189
CALL
Canadian Pacific Kansas City
CP
$81B
| $247K | 0.03% |
+3,700
| New | +$279K |
|
190
CALL
Sherwin-Williams
SHW
$84.8B
| $246K | 0.03% |
+1,200
| New | +$284K |
|
191
CALL
Gossamer Bio
GOSS
$101M
| $246K | 0.03% |
20,500
+15,500
| +310% | +$192K |
|
|
SGMO
192
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $245K | 0.03% |
+50,000
| New | +$257K |
|
|
NOAH
193
Noah Holdings
NOAH
$590M
| $242K | 0.03% |
+18,335
| New | +$312K |
|
194
CALL
Align Technology
ALGN
$12.9B
| $228K | 0.03% |
+1,100
| New | +$283K |
|
195
Automatic Data Processing
ADP
$109B
| $226K | 0.03% |
+1,000
| New | +$236K |
|
196
PUT
SIGA Technologies
SIGA
$240M
| $222K | 0.03% |
+21,600
| New | +$347K |
|
|
LBAI
197
DELISTED
Lakeland Bancorp Inc
LBAI
| $210K | 0.03% |
13,087
+2,087
| +19% | +$33.2K |
|
|
ORKA
198
PUT
Oruka Therapeutics
ORKA
$5.31B
| $206K | 0.03% |
8,333
| – | – |
|
199
PUT
Snap
SNAP
$7.96B
| $201K | 0.03% |
20,500
+5,000
| +32% | +$58.2K |
|
200
CALL
Royal Caribbean
RCL
$86.8B
| $197K | 0.03% |
5,200
| – | – |
|
Similar funds
EAM
CAM
CCM
GPCM
MAM
BGCI
TPL
RC
SG3 Management's Q3 2022 Portfolio in Review
As of Q3 2022, SG3 Management held 510 positions worth $746M, down 12% from $852M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
SG3 Management withdrew a net $67.1M in Q3 2022, closing 238 positions and reducing 59 holdings. Its most notable exit was KraneShares CSI China Internet ETF, an estimated $6.55M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 7.3% of assets, up from 0.21% a quarter earlier, followed by Communication Services and Technology.
Against the trend, SG3 Management opened a new position in Tesla worth $47M.
- SG3 Management's largest Q3 2022 buy was Tesla: 177,200 shares worth $47M.
- SG3 Management added most to Apellis Pharmaceuticals in Q3 2022, an estimated $2.3M increase.
- SG3 Management's biggest Q3 2022 reduction was LivaNova, cutting an estimated $1.29M.
- SG3 Management fully exited KraneShares CSI China Internet ETF in Q3 2022, selling an estimated $6.55M.
- SG3 Management's ten largest holdings make up 44% of its $746M portfolio in Q3 2022.
- SG3 Management opened 122 new positions and closed 238 in Q3 2022.
- SG3 Management's portfolio value fell 12% quarter-over-quarter to $746M.
Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.